GeoVax Appoints Chief Scientific Officer

GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, has appointed Mark J. Newman, Ph.D. as Chief Scientific Officer.

Dr. Newman, previously served the company as vice president of research and development from 2010 to 2013, and joins GeoVax on a half-time basis. The other portion of his working time will be devoted primarily to his work at NewMark Diagnostics, which he founded in 2016.  He previously served in senior management positions at PaxVax, Pharmexa A/S, Epimmune, Vaxcel, Apollon, and Cambridge Biotech. During his 30-year career he shepherded the development of experimental vaccine and adjuvant products through preclinical research and into Phase 1 & 2 clinical testing.

David Dodd, GeoVax President and CEO, said, “We are delighted to welcome Mark back to GeoVax and look forward to his guidance as we enter this pivotal period in the company’s evolution.  His familiarity with the management team and our MVA technology will translate into a rapid integration, for which we are excited.  We look forward working with Mark as we embark onto this next exciting phase for GeoVax.”